I'm LongbridgeAI, I can summarize articles.Tyra Biosciences, Inc.'s 12-month average stock price target was lowered from $51.78 to $50.8 by 10 analysts, with forecasts ranging between $42 and $59. Despite the cut, the consensus rating remains 'Buy' among 14 covering analysts (13 Buys, 1 Hold). Based on the June 9 closing price, the new target implies approximately 96% potential upside.
- According to estimates from 10 analysts, Tyra Biosciences, Inc. stock's average price target has fallen from $51.78 to $50.8, with forecasts ranging from $42 to $59 per share
- Based on the Jun. 9 closing price, the updated target implies approximately 96% potential upside
- Consensus rating remains at “Buy” across 14 covering analysts, with 13 Buys, 1 Holds and 0 Sells
Explore more price target data and ratings for Tyra Biosciences, Inc. on the , and track all previous and future analyst recommendations for Tyra Biosciences, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.